Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann, Sujin Park, Michael N. Hall
Nature reviews. Cancer (2018) Vol. 18, Iss. 12, pp. 744-757
Open Access | Times Cited: 896

Showing 1-25 of 896 citing articles:

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou, Tao Tao, Hongmei Li, et al.
Cell & Bioscience (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 732
Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Qing Yao, Xiaohao Wu, Chu Tao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 554
Metabolic coordination of T cell quiescence and activation
Nicole M. Chapman, Mark Boothby, Hongbo Chi
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 55-70
Closed Access | Times Cited: 552
The role of ubiquitination in tumorigenesis and targeted drug discovery
Lu Deng, Tong Meng, Lei Chen, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 524
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian, Xiaoyi Li, Jinhua Zhang
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 755-755
Open Access | Times Cited: 508
mTOR: Role in cancer, metastasis and drug resistance
Avaniyapuram Kannan Murugan
Seminars in Cancer Biology (2019) Vol. 59, pp. 92-111
Closed Access | Times Cited: 394
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Le Yu, Jessica Wei, Pengda Liu
Seminars in Cancer Biology (2021) Vol. 85, pp. 69-94
Closed Access | Times Cited: 385
Sex differences in cancer mechanisms
Joshua B. Rubin, J. S. Lagas, Lauren Broestl, et al.
Biology of Sex Differences (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 274
Lactate in the tumour microenvironment: From immune modulation to therapy
Zi-Hao Wang, Wenbei Peng, Pei Zhang, et al.
EBioMedicine (2021) Vol. 73, pp. 103627-103627
Open Access | Times Cited: 270
Meta-hallmarks of aging and cancer
Carlos López-Otı́n, Federico Pietrocola, David Roiz‐Valle, et al.
Cell Metabolism (2023) Vol. 35, Iss. 1, pp. 12-35
Open Access | Times Cited: 264
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Carla Riera‐Domingo, Annette Audigé, Sara Granja, et al.
Physiological Reviews (2019) Vol. 100, Iss. 1, pp. 1-102
Open Access | Times Cited: 251
Phase Separation as a Missing Mechanism for Interpretation of Disease Mutations
Brian Tsang, Iva Pritišanac, Stephen W. Scherer, et al.
Cell (2020) Vol. 183, Iss. 7, pp. 1742-1756
Open Access | Times Cited: 222
Immune control by amino acid catabolism during tumorigenesis and therapy
Henrique Lemos, Lei Huang, George C. Prendergast, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 3, pp. 162-175
Open Access | Times Cited: 219
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Elodie Villa, Eunüs S. Ali, Umakant Sahu, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 688-688
Open Access | Times Cited: 219
CCL5/CCR5 axis in human diseases and related treatments
Zhen Zeng, Tianxia Lan, Yuquan Wei, et al.
Genes & Diseases (2021) Vol. 9, Iss. 1, pp. 12-27
Open Access | Times Cited: 206
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Cedric Magaway, Eugene Kim, Estela Jacinto
Cells (2019) Vol. 8, Iss. 12, pp. 1584-1584
Open Access | Times Cited: 191
Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression
Meilin Weng, Wankun Chen, Xiang-yuan Chen, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 189
mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
Karen Griselda de la Cruz-López, Mariel Esperanza Toledo Guzmán, Elizabeth Sánchez, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 178
Cancer nanotechnology: current status and perspectives
Jessica A. Kemp, Young Jik Kwon
Nano Convergence (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 178
Cysteine metabolic circuitries: druggable targets in cancer
Vasco D. B. Bonifácio, Sofia A. Pereira, Jacinta Serpa, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 862-879
Open Access | Times Cited: 169
Structural basis for the docking of mTORC1 on the lysosomal surface
Kacper B. Rogala, Xin Gu, Jibril F. Kedir, et al.
Science (2019) Vol. 366, Iss. 6464, pp. 468-475
Open Access | Times Cited: 168
Regulation of mTORC2 Signaling
Wenxiang Fu, Michael N. Hall
Genes (2020) Vol. 11, Iss. 9, pp. 1045-1045
Open Access | Times Cited: 166
Multifaceted role of branched-chain amino acid metabolism in cancer
Hui Peng, Yingfei Wang, Weibo Luo
Oncogene (2020) Vol. 39, Iss. 44, pp. 6747-6756
Open Access | Times Cited: 164
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Begoña Alday-Parejo, Roger Stupp, Curzio Rüegg
Cancers (2019) Vol. 11, Iss. 7, pp. 978-978
Open Access | Times Cited: 149
The ins and outs of serine and glycine metabolism in cancer
Shauni Lien Geeraerts, Elien Heylen, Kim De Keersmaecker, et al.
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 131-141
Closed Access | Times Cited: 147
Page 1 - Next Page

Scroll to top